Shopping Cart
- Remove All
Your shopping cart is currently empty
Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $31 | In Stock | |
| 25 mg | $66 | In Stock | |
| 50 mg | $113 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock |
| Description | Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson's disease. |
| In vivo | Valiglurax (0.3-30 mg/kg; po) reversed haloperidol-induced catalepsy (HIC) in rats[1]. |
| Synonyms | VU-2957, VU2957, VU-0652957, VU0652957, VU 2957, VU 0652957 |
| Molecular Weight | 329.28 |
| Formula | C16H10F3N5 |
| Cas No. | 1976050-09-5 |
| Smiles | C(F)(F)(F)C=1C2=C(C=C(NC=3C=4C(NN3)=NC=CC4)C=C2)C=CN1 |
| Relative Density. | 1.530 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (341.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (12.15 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.